SOD1 and amyotrophic lateral sclerosis: Participants in this study must carry a rapid progressive SOD1 variant (mostly p.Ala5Val), be clinically presymptomatic for ALS, and have a plasma NfL level below the predefined threshold of 44 pg/mL, which minimizes the false‐positive rate.